1
|
Hong X, Chen Q, Ding L, Liang Y, Zhou N,
Fang W, Chen X and Wu H: Clinical benefit of continuing crizotinib
therapy after initial disease progression in Chinese patients with
advanced ALK-rearranged non-small-cell lung cancer. Oncotarget.
8:41631–41640. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Pearce A, Bradley C, Hanly P, O'Neill C,
Thomas AA, Molcho M and Sharp L: Projecting productivity losses for
cancer-related mortality 2011–2030. Bmc Cancer. 16:8042016.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Midha A, Dearden S and McCormack R: EGFR
mutation incidence in non-small-cell lung cancer of adenocarcinoma
histology: A systematic review and global map by ethnicity
(mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
|
4
|
Huang H, Du T, Xu G, Lai Y, Fan X, Chen X,
Li W, Yue F, Li Q, Liu L and Li K: Matrine suppresses invasion of
castration-resistant prostate cancer cells by downregulating
MMP-2/9 via NF-κB signaling pathway. Int J Oncol. 50:640–648. 2017.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Liu Z, Zhang Y, Tang Z, Xu J, Ma M, Pan S,
Qiu C, Guan G and Wang J: Matrine attenuates cardiac fibrosis by
affecting ATF6 signaling pathway in diabetic cardiomyopathy. Eur J
Pharmacol. 804:21–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Huang WC, Chan CC, Wu SJ, Chen LC, Shen
JJ, Kuo ML, Chen MC and Liou CJ: Matrine attenuates allergic airway
inflammation and eosinophil infiltration by suppressing eotaxin and
Th2 cytokine production in asthmatic mice. J Ethnopharmacol.
151:470–477. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yong J, Wu X and Lu C: Anticancer advances
of matrine and its derivatives. Curr Pharm Des. 21:3673–3680. 2015.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Qian L, Liu Y, Xu Y, Ji W, Wu Q, Liu Y,
Gao Q and Su C: Matrine derivative WM130 inhibits hepatocellular
carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling
pathways. Cancer Lett. 368:126–134. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Ma Y, Zou F, Xiong J, Wan W, Yin L, Li X,
Bei Z, Yuan L, Meng S, Wang J and Song G: Effect of Matrine on HPAC
cell migration by down-regulating the expression of MT1-MMP via Wnt
signaling. Cancer Cell Int. 15:592015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Xie M, Yi X, Wang R, Wang L, He G, Zhu M,
Qi C, Liu Y, Ye Y, Tan S and Tang A: 14-Thienyl methylene matrine
(YYJ18), the derivative from matrine, induces apoptosis of human
nasopharyngeal carcinoma cells by targeting MAPK and PI3K/Akt
pathways in vitro. Cell Physiol Biochem. 33:1475–1483. 2014.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Wei L, Yao Y, Zhao K, Huang Y, Zhou Y,
Zhao L, Guo Q and Lu N: Oroxylin A inhibits invasion and migration
through suppressing ERK/GSK-3β signaling in snail-expressing
non-small-cell lung cancer cells. Mol Carcinog. 55:2121–2134. 2016.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Ho MY, Liang SM, Hung SW and Liang CM:
MIG-7 controls COX-2/PGE2-mediated lung cancer metastasis. Cancer
Res. 73:439–449. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Chen J, Mei Q, Xu YC, Du J, Wei Y and Xu
ZM: Effects of Matrine Injection on T-lymphocyte subsets of
patients with malignant tumor after gamma knife radiosurgery. Zhong
Xi Yi Jie He Xue Bao. 4:78–79. 2006.(In Chinese). View Article : Google Scholar : PubMed/NCBI
|
14
|
Yin H, Que R, Liu C, Ji W, Sun B, Lin X,
Zhang Q, Zhao X, Peng Z, Zhang X, et al: Survivin-targeted drug
screening platform identifies a matrine derivative WM-127 as a
potential therapeutics against hepatocellular carcinoma. Cancer
Lett. 425:54–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
15
|
Wu L, Wang G, Liu S, Wei J, Zhang S, Li M,
Zhou G and Wang L: Synthesis and biological evaluation of matrine
derivatives containing benzo-α-pyrone structure as potent anti-lung
cancer agents. Sci Rep. 6:359182016. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhou N, Li J, Li T, Chen G, Zhang Z and Si
Z: Matrine-induced apoptosis in Hep3B cells via the inhibition of
MDM2. Mol Med Rep. 15:442–450. 2017. View Article : Google Scholar : PubMed/NCBI
|
17
|
Wu L, Wang G, Wei J, Huang N, Zhang S,
Yang F, Li M, Zhou G and Wang L: Matrine derivative YF-18 inhibits
lung cancer cell proliferation and migration through
down-regulating Skp2. Oncotarget. 8:11729–11738. 2017.PubMed/NCBI
|
18
|
Ali M, Wu Y, Ghosh D, Do BH, Chen K,
Dawson MR, Fang N, Sulchek TA and El-Sayed MA: Nuclear
membrane-targeted gold nanoparticles inhibit cancer cell migration
and invasion. ACS Nano. 11:3716–3726. 2017. View Article : Google Scholar : PubMed/NCBI
|
19
|
Labernadie A, Kato T, Brugués A,
Serra-Picamal X, Derzsi S, Arwert E, Weston A, González-Tarragó V,
Elosegui-Artola A, Albertazzi L, et al: A mechanically active
heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to
drive cancer cell invasion. Nat Cell Biol. 19:224–237. 2017.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Jacquemet G, Baghirov H, Georgiadou M,
Sihto H, Peuhu E, Cettour-Janet P, He T, Perälä M, Kronqvist P,
Joensuu H and Ivaska J: L-type calcium channels regulate filopodia
stability and cancer cell invasion downstream of integrin
signalling. Nat Commun. 7:132972016. View Article : Google Scholar : PubMed/NCBI
|
21
|
Wu X, Zhou J, Cai D and Li M: Matrine
inhibits the metastatic properties of human cervical cancer cells
via downregulating the p38 signaling pathway. Oncol Rep.
38:1312–1320. 2017. View Article : Google Scholar : PubMed/NCBI
|
22
|
Yang SF, Yang WE, Kuo WH, Chang HR, Chu SC
and Hsieh YS: Antimetastatic potentials of flavones on oral cancer
cell via an inhibition of matrix-degrading proteases. Arch Oral
Biol. 53:287–294. 2008. View Article : Google Scholar : PubMed/NCBI
|
23
|
Zhou LE, Wang WJ, Bai JY and Cheng GF:
Effects of ginkgolide B on arachidonic acid metabolizing enzymes
and level of intracellular calcium in rat polymorphonuclear
leukocytes. Yao Xue Xue Bao. 36:92–95. 2001.(In Chinese).
PubMed/NCBI
|
24
|
Li H, Tan G, Jiang X, Qiao H, Pan S, Jiang
H, Kanwar JR and Sun X: Therapeutic effects of matrine on primary
and metastatic breast cancer. Am J Chin Med. 38:1115–1130. 2010.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Davis NM, Sokolosky M, Stadelman K, Abrams
SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro
A, et al: Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in
breast cancer: Possibilities for therapeutic intervention.
Oncotarget. 5:4603–4650. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Sagredo AI, Sagredo EA, Cappelli C, Báez
P, Rodrigo AM, Blanco C, Tapia JC, Echeverria C, Cerda O, Stutzin
A, et al: TRPM4 regulates Akt/GSK3-β activity and enhances
β-catenin signaling and cell proliferation in prostate cancer
cells. Mol Oncol. 12:151–165. 2018. View Article : Google Scholar : PubMed/NCBI
|
27
|
Zhang PP, Wang PQ, Qiao CP, Zhang Q, Zhang
JP, Chen F, Zhang X, Xie WF, Yuan ZL, Li ZS and Chen YX:
Differentiation therapy of hepatocellular carcinoma by inhibiting
the activity of AKT/GSK-3β/β-catenin axis and TGF-β induced EMT
with sophocarpine. Cancer Lett. 376:95–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
28
|
Wu J, Hu G, Dong Y, Ma R, Yu Z, Jiang S,
Han Y, Yu K and Zhang S: Matrine induces Akt/mTOR signalling
inhibition-mediated autophagy and apoptosis in acute myeloid
leukaemia cells. J Cell Mol Med. 21:1171–1181. 2017. View Article : Google Scholar : PubMed/NCBI
|
29
|
Niu H, Zhang Y, Wu B, Zhang Y, Jiang H and
He P: Matrine induces the apoptosis of lung cancer cells through
downregulation of inhibitor of apoptosis proteins and the Akt
signaling pathway. Oncol Rep. 32:1087–1093. 2014. View Article : Google Scholar : PubMed/NCBI
|
30
|
Hseu YC, Thiyagarajan V, Tsou HT, Lin KY,
Chen HJ, Lin CM, Liao JW and Yang HL: In vitro and in vivo
anti-tumor activity of CoQ0 against melanoma cells: inhibition of
metastasis and induction of cell-cycle arrest and apoptosis through
modulation of Wnt/β-catenin signaling pathways. Oncotarget.
7:22409–22426. 2016. View Article : Google Scholar : PubMed/NCBI
|
31
|
Xu G, Yu H, Shi X, Sun L, Zhou Q, Zheng D,
Shi H, Li N, Zhang X and Shao G: Cisplatin sensitivity is enhanced
in non-small cell lung cancer cells by regulating
epithelial-mesenchymal transition through inhibition of eukaryotic
translation initiation factor 5A2. BMC Pulm Med. 14:1742014.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Chen L, Li YC, Wu L, Yu GT, Zhang WF,
Huang CF and Sun ZJ: TRAF6 regulates tumour metastasis through EMT
and CSC phenotypes in head and neck squamous cell carcinoma. J Cell
Mol Med. 22:1337–1349. 2018.PubMed/NCBI
|
33
|
Liu L, Zhou XM, Yang FF, Miao Y, Yin Y, Hu
XJ, Hou G, Wang QY and Kang J: TRIM22 confers poor prognosis and
promotes epithelial-mesenchymal transition through regulation of
AKT/GSK3β/β-catenin signaling in non-small cell lung cancer.
Oncotarget. 8:62069–62080. 2017.PubMed/NCBI
|